{
    "nctId": "NCT03881384",
    "briefTitle": "Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients",
    "officialTitle": "Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients During Neoadjuvant Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "The concentration of circulating DNA(ctDNA)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients pre- or post-menopausal must have histologically confirmed early stage/locally advanced invasive breast cancer;\n* Tumor size \u2265 0.5cm (clinical or radiographic measurements);\n* Any nodal status allowed;\n* Age \\> 18 years old;\n* Felt to be a possible candidate for neoadjuvant systemic therapy by their treating physician;\n* ECOG score\\<=2;\n\nExclusion Criteria:\n\n* Known metastatic disease;\n* With serious heart, lung, liver diseases;\n* Poor cardiac function;\n* Pregnant;\n* Patients with other malignant tumor or treated before;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}